Cellectis (CLLS)

• Market cap: $470M
• 1 day: -10.34%
• 5 days: -1.27%
• 1 month: 28.22%
• 3 months: 61.94%
• 6 months: 241.61%
• Year to date: 158.56%
• 1 year: 152.97%
• 5 years: -85%
• 10 years: -82.63%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222